TrialReader


Long-term Impact of NMDAR Encephalitis

NCT06609044 — Completed, 20 participants, Hospices Civils de Lyon

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Social and Psychological Long-term Impact of NMDA Receptor Encephalitis

RegistryNCT06609044, acronym SAPIENCE2
StatusCompleted
Study typeObservational
Enrollment20 (Actual)
SponsorHospices Civils de Lyon (Other)
ConditionsAutoimmune Encephalitis
Datesstart 2024-12-16, primary completion 2025-04-04, completion 2025-04-04, first posted 2024-09-23, last updated 2025-12-23
Locations1 site in France

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Autoimmune Encephalitis

-Summary

NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored.

Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.

Expand all sections  ·  Collapse all

+Detailed description

This study will help improve the management of patients with anti-NMDAR encephalitis :

* By providing the first assessment of long-term cognitive, psychological and social consequences
* By characterizing the patient's journey through the disease
* By developing a standardized neuropsychological assessment which will improve the assessment of the patient in the post-acute phase As well as improving patient care in the long term through the drafting of specific medical recommendations.

+Arms and interventions

ArmTypeInterventionsDescription
Anti-NMDAR encephalitis patients.Patients over 18 years old with NMDAR encephalitis.

+Outcome measures

Primary outcomes

  • Psychosocial questionnaires of patients with anti-NMDAR encephalitis after the acute phase of the disease. [50 MINUTES]: Neuropsychological Questionnaires : * RAVLT questionnaire (no score) * EMPAN questionnaire (no score)
  • Analysis of cognitive assessments of patients with anti-NMDAR encephalitis after the acute phase of the disease. [40 MINUTES]: Score of PROMs questionnaires : * FSS (score : /63) * HADS (score : /42) * EQ5D5L (score : /100) * BDI-II (no score ) * MMQ (no score) * PSQI (no score)
  • Patient's experience of the disease [1 Year]: Score of Clinical questionnaire about patient's experience of the disease

+Eligibility

Sex: All, ages: 18 Years to 80 Years

Inclusion Criteria:

* Patients with NMDAR encephalitis
* Age ≥ 18 years old
* Patient affiliated to a social security system
* No opposition from the patient

Exclusion Criteria:

* Patients whithout NMDAR encephalitis
* Age \< 18 years old
* Patient under guardianship or curatorship
* Patient with neurological disorders pre-existing encephalitis

+Locations (1)

FacilityCityCountryStatus
Centre de référence des syndromes neurologies paranéoplasiques et encéphalites auto-immunes - Hôpital neurologiques Pierre WERTHEIMERBronFrance

+Publications

  • Results publication: Boeken OJ, Heine J, Duda-Sikula M, Patricio V, Picard G, Buttard C, Benaiteau M, Mendes A, Howard F, Easton A, Kurpas D, Honnorat J, Dalmau J, Finke C. Assessment of long-term psychosocial outcomes in N-methyl-D-aspartate receptor encephalitis - the SAPIENCE study protocol. BMC Neurol. 2024 Sep 6;24(1):322. doi: 10.1186/s12883-024-03842-6. PMID 39242986

+Investigators

  • Jérôme HONNORAT, MD, Principal investigator, Centre de référence des syndromes neurologies paranéoplasiques et encéphalites auto-immunes - Hôpital neurologiques Pierre WERTHEIMER - Groupement hospitalier Est - Hospices civiles de Lyon

My Notes